Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06904482 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Interventions: Haplo-Identical / Cord Blood Transplant (Biological) to Haplo-Identical / Cord Blood Transplant (Biological)
    • Eligibility criteria expanded, about 30 words
    • Secondary endpoints: details revised at 2 of 45 entries
  2. Eligibility criteria expanded, about 15 wordsv9
  3. Start date changed from estimate of Jul 29, 2025 to Aug 13, 2025v8
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2025 to Jul 29, 2025
    • Site details revised
    v7
  5. Start date: May 2025 to Jul 2025v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date: Apr 2025 to May 2025v5
  2. Start date: Apr 1, 2025 to Apr 2025v4
  3. Re-verified, no change to tracked fieldsv3
  4. Secondary endpoints: details revised at 3 of 45 entries
    • Study description revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Trial Details
NCT Number NCT06904482
Lead Sponsor Case Comprehensive Cancer Center
Conditions
(from sponsor)		 aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
Related terms Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov